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AbstrAct
Objective Primary percutaneous coronary intervention 
(P- PCI) has demonstrated its efficacy in patients with 
ST segment elevation myocardial infarction (STEMI). 
However, patients with STEMI ≥75 years receive less P- 
PCI than younger patients despite their higher in- hospital 
morbimortality. The objective of this analysis was to 
determine the effectiveness of P- PCI in patients with 
STEMI ≥75 years.
Methods We included 979 patients with STEMI ≥75 
years, from the ATención HOspitalaria del Síndrome 
coronario study, a registry of 8142 consecutive patients 
with acute coronary syndrome admitted at 31 Spanish 
hospitals in 2014–2016. We calculated a propensity score 
(PS) for the indication of P- PCI. Patients that received or 
not P- PCI were matched by PS. Using logistic regression, 
we compared the effectiveness of performing P- PCI versus 
non- performance for the composite primary event, which 
included death, reinfarction, acute pulmonary oedema or 
cardiogenic shock during hospitalisation.
Results Of the included patients, 81.5 % received P- PCI. 
The matching provided two groups of 169 patients with 
and without P- PCI. Compared with its non- performance, 
P- PCI presented a composite event OR adjusted by PS of 
0.55 (95% CI 0.34 to 0.89).
Conclusions Receiving a P- PCI was significantly 
associated with a reduced risk of major intrahospital 
complications in patients with STEMI aged 75 years or 
older.
IntROduCtIOn
Coronary heart disease is the leading indi-
vidual cause of death in Spain as in all 
Europe. Although mortality from coronary 
heart disease is decreasing, the number of 
events is increasing due to the ageing of the 
population,1 with an expected increase in 
acute coronary syndrome (ACS) in the popu-
lation aged 75 years or older.2 The National 
Institute of Statistics estimates the Spanish 
population of ≥75 years in 2012 in more than 
4 million (9%) and expects that this figure 
Key questions
What is already known about this subject?
 ► Primary percutaneous coronary intervention (P- 
PCI) significantly decreases mortality of patients 
presenting with ST elevation myocardial infarction 
(STEMI) and constitutes a type I A indication in the 
international clinical guidelines for the treatment of 
acute coronary syndrome (ACS).
 ► Despite this recommendation, patients aged 
≥75 years receives less PCI- P to the high preva-
lence of comorbidities (eg, like chronic renal failure 
or chronic obstructive pulmonary disease) and in-
creased risk of bleeding and other complications.
What does this study add?
 ► Our study points out the significant decrease of ad-
verse events during the hospitalisation of patients 
aged ≥75 years with STEMI when undergoing P- PCI 
in spite of their comorbidities.
How might this impact on clinical practice?
 ► Our results should extend the indication of PCI to pa-
tients aged ≥75 years to reduce their mortality when 
presenting a STEMI.
Open Heart
2 Fernández- Bergés D, et al. Open Heart 2020;7:e001169. doi:10.1136/openhrt-2019-001169
will increase—if the estimated demographic growth is 
maintained—up to 23% of the total population in 2052.3 
At present, different series place the prevalence of ACS 
in this population above 30%, exceeding 40% in some 
national series.4
The treatment of ST segment elevation myocardial 
infarction (STEMI) includes performing a percuta-
neous coronary intervention (PCI) as soon as possible 
called primary PCI (P- PCI) with indication I- A (I = 
evidence and /or general agreement that a given treat-
ment or procedure is beneficial, useful, effective. A = 
data derived from multiple randomized clinical trial or 
large non- randomized studies).5 If P- PCI is not available 
within 120 min from the first medical contact, fibrinolysis 
should be performed, except for contraindications, with 
subsequent angiographic study and, if possible, elective 
PCI (I- A). According to the most recent guide, there is 
no upper age limit for the recommendation of PCI, and 
therefore, all patients who meet the criteria regardless of 
their age should receive it.5 However, the utility of P- PCI 
in patients with STEMI ≥75 years is discussed, and this 
population receives fewer reperfusion treatments, both 
invasive and pharmacological.6 The lower reperfusion of 
elderly patients is probably due to the presence of atypical 
symptoms and to the delay in diagnosis, to their frequent 
comorbidity and to the higher rate of complications they 
may present (contrast nephropathy, major bleedings and 
so on).5–7
The lower invasive treatment in patients with STEMI 
≥75 years is also due to the fact that randomised clinical 
trials usually do not include older patients, and if they 
do, they are highly selected. Therefore, the claim of the 
2007 American Heart Association 7 referring to the need 
for clinical studies that include patients over 65 years has 
not lost its validity.
Our objective in the present study was to analyse 
whether the performance of a P- PCI reduces complica-
tions (death, reinfarction, acute pulmonary oedema or 
cardiogenic shock) during hospitalisation in patients 
with STEMI ≥75 years compared with patients with the 
same characteristics to which P- PCI was not performed.
MetHOds
design
A prospective, consecutive, multicentric and national 
ACS registry was designed: the ATención HOspitalaria 
del Síndrome coronario (ATHOS) registry.8 This registry 
included 8142 patients diagnosed with ACS admitted 
consecutively in 31 Spanish hospitals during 2014–2016. 
For the present study, patients from the ATHOS registry 
who had an STEMI on admission and who were ≥75 years 
old (n=979 patients) were selected.
Patient and public involvement
Patients or the public were not involved in the design, or 
conduct, or reporting, or dissemination of our research
study variables
Age, sex, tobacco consumption, history of diabetes, 
hypertension, cardiovascular disease (myocardial infarc-
tion, angina, heart failure, stroke, PCI and coronary 
artery bypass surgery) and related comorbidities (chronic 
obstructive pulmonary disease and chronic renal failure 
(CRF)) were recorded. Glycaemia and creatinine were 
collected in the admission analytical test. From the creati-
nine value, the estimated glomerular filtration rate (GFR) 
was calculated in mL/min/1.73 m2 using the formula 
Modification of Diet in Renal disease.
During hospitalisation, coronary angiography and 
P- PCI were recorded, as well as the prescription of medi-
cation (antiplatelet agents, heparin, ACE inhibitors, beta- 
blockers and diuretics). The onset of heart failure (acute 
pulmonary oedema and cardiogenic shock) was recorded 
at admission and during hospitalisation by the Killip and 
Kimball classification.9 As major bleeding complications, 
the fall of >3 g of haemoglobin, the need for transfusion 
or surgery and intracranial bleeding were considered.
events of interest
The primary event consisted of a composite variable that 
included death, reinfarction, acute pulmonary oedema 
or cardiogenic shock during hospitalisation.
statistical analysis
For the description of the continuous variables, the mean 
and SD were used when the variable followed a normal 
distribution and the median and IQR were used other-
wise. Categorical variables were described as percentages. 
Comparisons of continuous variables between groups 
according to the performance of P- PCI were performed 
using the Student’s t- test or the Mann- Whitney test if the 
distribution was not normal. Categorical variables were 
compared between the same groups using the χ2 test.
To evaluate the effect of P- PCI on the primary endpoint 
(death, reinfarction or Killip III- IV during hospitalisa-
tion), a logistic regression model was used in patients 
matched by propensity score (PS) to receive P- PCI. A 
PS was calculated for P- PCI using a logistic regression 
model. For the PS model, all variables associated with 
performing P- PCI were included as independent vari-
ables and P- PCI as a dependent variable. Subsequently, 
patients with and without P- PCI were paired from the 
logit- PS with a tolerance of 0.2 times their SD.10 After the 
pairing of the patients, the standardised differences of 
the variables between paired patients with and without 
P- PCI were analysed. It was assumed that the variables 
were balanced if the standardised differences were <10.11 
Finally, we included the paired patients in a logistic 
regression model, in which the dependent variable was 
the event of interest, and the independent variables were 
the P- PCI performance and the variables that were not 
well balanced in the process of matching by PS.
All analyses were performed with the statistical 
programme R (V.3.2.3) .
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Results
Table 1 showed the characteristics and evolution in 
admission of the 979 patients aged ≥75 years with STEMI 
included in the analysis. P- PCI was performed in 798 
(81.5%) of these patients. We observed that compared 
with patients who did not receive a P- PCI, the patients 
who did receive it had significantly younger age, higher 
prevalence of tobacco consumption and lower preva-
lence of angina, heart failure, stroke and previous CRF. 
On admission, patients who received P- PCI had a lower 
degree of heart failure and a lower prevalence of glomer-
ular filtration rate <60 mL/min/1.73 m2.
In patients who received P- PCI, the indication of medi-
cation of proven efficacy in the reduction of cardiovas-
cular events such as beta- blockers, ACE inhibitors or 
double antiplatelet treatment were significantly more 
used. Patients with P- PCI received more heparin in acute 
phase but less diuretics compared with patients without 
P- PCI. There were no significant differences in the inci-
dence of major bleedings between both groups. There 
were statistically significant differences between both 
groups with respect to the presentation of the combined 
event during hospitalisation.
Age, presence of heart failure on admission, GFR 
<60 mL/min at admission, previous angina, previous 
heart failure and previous stroke, all of them with statisti-
cally significant differences, were included in the estima-
tion of the PS. The area under curve of the PS model was 
0.68 (95% CI 0.64 to 0.73).
In the PS model, two groups of 169 patients could 
be included and compared. Table 2 showed the vari-
ables included in the PS in paired patients as well as 
the standardised differences of the variables before 
and after matching. There were no significant differ-
ences in these variables between the two groups. The 
standardised differences of the variables included in 
the PS decreased when matching the patients. Only 
the variables previous angina and glomerular filtration 
<60 mL/min at admission were not correctly balanced 
since they presented a standardised difference slightly 
above 10 of the corresponding SD. These two variables 
were included in the final model to predict the risk of 
the event of interest.
The final logistic regression model (table 3) showed 
that patients who had received a P- PCI compared with 
those who had not received it, had a lower risk of dying or 
presenting with reinfarction, acute pulmonary oedema 
or cardiogenic shock during the hospitalisation (OR 
0.55, 95% CI 0.34 to 0.89).
dIsCussIOn
Our study shows that the use of a P- PCI in a population 
of 75 years or older with a STEMI significantly reduces 
complications during hospitalisation, including 
mortality, reinfarction, pulmonary oedema and cardio-
genic shock.
The elderly population that is part of ATHOS registry8 
has an average age of 83.1 (5.9) years old with an 
important index of comorbidities, constituting a repre-
sentative sample of the elderly patient of a European 
country. After an adequate characterisation and the 
use of a validated statistical procedure for observational 
studies,12 we have seen that P- PCI in elderly patients with 
STEMI reduces the risk of presenting complications 
during hospital admission.
Patients aged ≥75 years old with non- STEMI have 
received special attention in recent years,13 14 but more 
rare, and in some cases inconclusive, are the studies in 
patients with STEMI, particularly assessing the use of 
P- PCI.15 If we take into account the important Spanish 
multicentre studies published in the first decade of 
this century, only the TRIANA16 clinical trial and the 
ESTROFA17 registry included patients aged >75 years 
old who presented with STEMI and in whom P- PCI was 
performed. TRIANA showed a trend towards better 
survival when P- PCI was used compared with fibrino-
lysis, and ESTROFA described that elderly STEMI 
patients had a high prevalence of renal failure and 
multivessel disease.
The CASTUO single- centre observational study,4 
which included patients with acute myocardial infarc-
tion, found improvement in survival in patients aged 
>75 when PCI was indicated during admission, both 
in the admission phase and during follow- up. The 
rest of the multicentre Spanish registries that include 
patients with STEMI did not study in particular the 
subgroup of elderly patients or the indication of 
P- PCI.18 19 Of the international multicentre studies 
that include both STEACS and NSTEACS, ACACIA,20 
AMIS Plus21 and MINAP22 showed a reduction in 
mortality associated with invasive treatment in elderly 
patients with ACS both with and without ST segment 
elevation, although they did not analyse the P- PCI 
indication.
The impact and use of PCI in STEMI, between 
2003and 2012 in Spain, has recently been evaluated by 
Cequier et al.23 In this study of 302 471 patients, 116 621 
received PCI (38.6%), 46 720 fibrinolysis (15.4%) and 
139 130 had no indication of reperfusion  (46%). The 
mean age of the patients who received PCI, fibrinolysis, 
or neither was 63.4, 63.7 and 71.8 years old, respectively. 
This shows a significant gradient in the age of PCI indi-
cation that penalises the elderly patients given that 
the mortality for the PCI group was 4.8% versus 17.3% 
for the group without any reperfusion therapy. The 
number of elderly persons is rapidly growing in Europe, 
and their proportion in the population is expected to 
increase. Elderly STEMI patients are typically treated 
less aggressively than younger patients because they 
have more comorbidities and risk of bleeding.5–7 For 
the same reasons they are also under- represented in 
clinical trials.
This last aspect is particularly important because it 
is one of the most important causes when it comes to 
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Table 1 Characteristics of patients aged 75 years and older
Total n=979 No P- PCI n=181 P- PCI n=798 P value
Age 83.1 (6.01) 85.0 (6.20) 82.7 (5.89) <0.001
Sex women (%) 39.8 46.4 38.3 0.055
Killip III- IV admission (%) 15.3 27.6 12.5 <0.001
GFR <60 mL/min (%) 42.4 52.3 40.1 0.004
Glucose <126 mg/dL (%) 65.4 68.2 64.7 0.432
Diabetes mellitus (%) 0.668
  No 65.7 68.0 65.2
  Yes, diet control 3.47 2.76 3.63
  Yes, OADs control 21.5 18.8 22.1
  Yes, insulin control 8.89 10.5 8.52
  Yes, diabetes in hospitalisation 0.51 0.00 0.63
Smoker (%) <0.004
  Never 64.5 75.1 62.0
  Actual 11.8 8.29 12.7
  Ex- smoker >30 days 23.7 16.6 25.3
Arterial hypertension 73.0 75.1 72.6 0.539
Previous MI 14.6 14.4 14.7 1.000
Previous angina 11.6 16.6 10.5 0.031
Previous CHF 4.60 10.5 3.26 <0.001
Previous stroke 9.60 13.8 8.65 0.047
Previous PCI 11.0 7.73 11.8 0.151
Previous CABG 2.15 2.76 2.01 0.568
COPD 13.6 14.9 13.3 0.646
CRF 13.8 19.9 12.4 0.012
Antiplatelet (%) <0.001
  None 4.19 8.29 3.26
  One antiplatelet* 5.52 16.6 3.01
  Combination† 90.3 75.1 93.7
Heparin hospitalisation (%) <0.001
  None 17.5 34.8 13.5
  UFH 41.5 12.2 48.1
LMWH 29.0 48.6 24.6
  UFH+LMWH 12.1 4.42 13.8
ACE inhibitors (%) 57.8 47.5 60.2 0.002
Beta- blockers (%) 55.5 48.6 57.0 0.049
Diuretics (%) 39.3 51.4 36.6 <0.001
Coronariography (%) <0.001
  No 10.4 56.4 0.00
  Yes 89.1 42.5 99.6
Major bleeding 3.16 2.90 4.42 0.405
Exitus, reinfartcion or Killip III- IV during hospitalisation 22.7 40.9 18.5 <0.001
Results with and without P- PCI.
*Only aspirin or ticlopidine or clopidogrel or others.
†Two antiplatelet drugs.
CABG, coronary artery bypass grafting; CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; CRF, chronic renal 
failure; GFR, glomerular filtration rate; LMWH, low molecular weight heparin; MI, myocardial Infarction; OADs, oral antidiabetic’s drugs; 
PCI, percutaneous coronary intervention; P- PCI, primary percutaneous coronary intervention; UFH, unfractioned heparin.
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Table 2 Characteristics of patients matched by propensity 
score and standardised differences in propensity score 
variables before and after matched
Matched n=169 n=169 P value
Age 85.0 (79.0; 88.0) 84.0 (79.0; 88.0) 0.507
Killip III- IV admission 42 (24.9%) 39 (23.1%) 0.799
GFR <60 mL/min 86 (50.9%) 77 (45.6%) 0.384
Previous angina 142 (84.0%) 148 (87.6%) 0.436
Previous CHF 153 (90.5%) 155 (91.7%) 0.848






Killip III- IV admission 38.29 4.15
GFR <60 mL/min 24.55 10.64
Previous angina 17.71 10.15
Previous CHF 28.84 4.15
Previous stroke 16.38 1.77
*Differences between groups based on the % of the SD of each 
individual variable.
CHF, chronic heart failure; GFR, glomerular filtration rate.
Table 3 Risk of death, reinfarction, acute pulmonary 
oedema or cardiogenic shock during hospitalisation in 
patients with STEMI aged ≥75 years undergoing P- PCI
OR 95% CI P value
P- PCI versus not done 0.552 0.342 to 0.892 0.015
GFR <60 mL 2.971 1.832 to 4.818 0.001
Previous angina 1.610 0.842 to 3.081 0.150
GFR, glomerular filtration rate; P- PCI, primary percutaneous 
coronary intervention.
justifying the lower indication of catheterisation and PCI 
in elderly patients.
This scenario constitutes a therapeutic challenge in the 
management of coronary artery disease elderly patients, a 
major concern for cardiac interventionists and surgeons. 
Our study shows the feasibility and benefits of intensive 
management with current clinical guidelines recommen-
dations of this population, despite their high comorbidity 
prevalence (eg, chronic kidney failure, COPD, diabetes 
mellitus and previous coronary heart disease or stroke).
Among these comorbidities, the most prominent are 
usually the existence of diabetes, anaemia and CRF. 
There is a potential risk of exacerbation of CRF when 
the patient is submitted to a procedure that includes 
iodinated contrast. In addition, double antiplatelet 
therapy in the elderly diabetic patient and with CRF 
increases the risk of bleeding after PCI.24 These risks 
may explain why the indication for PCI is lower in 
patients aged >75 years old due to fear of complications. 
Savonitto et al25 analyse the importance of emphasising 
CRF and anaemia by carefully adjusting the dose of 
antithrombotic drugs and choosing a radial approach 
in the PCI, which results in a lower risk of subsequent 
bleeding.26 The exacerbation of CRF by contrast mate-
rial and its way of preventing it continues to be a cause 
for concern and an unresolved discussion.27 Recently, 
the EUROTRACS study28 showed a reduction in 
mortality during hospital admission in elderly patients 
with ACS undergoing PCI who presented with CRF or 
diabetes. These results, together with the rest of the 
evidence, seem to indicate that, although a careful anal-
ysis of the life situation of the elderly patient should 
be made, the usual presence of comorbidities should 
not be assumed as a contraindication. An adequate clin-
ical assessment may be sufficient to avoid depriving a 
patient of the benefit of a proven treatment.
The success of P- PCI has been so remarkable that 
recommendations have been extended to improve the 
application of this treatment, which is closely linked to 
the time of completion.29 In Europe, the Stent for Life 
Initiative30 has become a very active platform supporting 
the indications and the use of clinical guidelines in the 
management of myocardial infarction, defining actions 
that improve compliance and helping to identify barriers 
that may arise. In Spain, the use of reperfusion strate-
gies has been improving year after year and, with this, 
mortality due to STEMI has decreased, and the incor-
poration of this European initiative has significantly 
increased the PCI rate in general and especially P- PCI.23
If we take into account that age is one of the variables 
that best predict mortality in ACS and that P- PCI is the 
most effective intervention to avoid it, it is clear to what 
extent it is important to establish its use and usefulness in 
the patients aged ≥75 years old who present with STEMI. 
We must also take into account the use of fibrinolysis as a 
valid alternative when times or distance prevent the real-
isation of a P- PCI, although there are greater bleeding 
risks in this population.31 32
Among the reasons that have traditionally been put 
forward to exclude those over 75 years of age and that 
have already been exposed, there is one,33 which we have 
not been able to explore, referring to the late arrival at 
the hospital of the elderly patient ‘outside the optimal 
window’ for perform a P- PCI. The European Society of 
Cardiology guidelines5 established that ‘a routine primary 
PCI strategy should be considered in patients presenting 
late (12–48 hours) after symptom onset’. This strategy 
should certainly be explored in depth.
In short, the elderly population with STEMI, due to 
the increase in prevalence, the benefits of P- PCI and the 
increased risk of bleeding secondary to the use of fibrino-
lytics, constitutes a group of special interest to be treated 
with invasive procedures.
The European Society of Cardiology Guidelines5 
states that ‘There is no upper age limit with respect to reper-
fusion, especially with primary PCI’ but is unusual that 
the decision is based only in one study16 that could not 
complete the estimated sample size due to the diffi-
culty of including patients older than 75 years. This 
Open Heart
6 Fernández- Bergés D, et al. Open Heart 2020;7:e001169. doi:10.1136/openhrt-2019-001169
situation, in addition to the difficulty of having suffi-
ciently statistically powered randomised clinical trials, 
shows that doctors themselves have an inclusion bias, 
finding intangible reasons to excluding elderly patients 
in P- PCI prospective protocols.
Because of this, we believe that it is necessary to rein-
force in daily clinical practice—that the person suffering 
from STEMI should always be considered to perform 
a P- PCI and balance the cost–benefit equation without 
excluding anyone by age. It is likely that in the immediate 
future we must refer to the elderly population as those 
over 85 years of age and include nonagenarians and even 
older.
The results of our study would support the indication of 
P- PCI as the treatment of choice in patients with STEMI 
≥75 years old.
limitations
The present study has the limitations of observational 
studies that explore the effect of the exposure to treat-
ments (eg, confounding, selection bias and potential 
reverse causation), which have been overcome by PS. The 
information brought up in our study is otherwise diffi-
cult to obtain in elderly patients because they tend to be 
excluded from clinical trials.
The relatively small sample size is another limitation. 
The difficulty of recruiting elderly patients is commonly 
referred to in the literature.
COnClusIOns
The performance of P- PCI is significantly associated with 
a lower risk of major complications in patients ≥75 years 
old admitted for a STEMI.
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